About this trial
This study examines how the psychedelic substance DMT affects the human brain when administered by the intravenous (IV) route. DMT is a naturally occurring chemical in the body that is thought to help improve mood when ingested in a continuously monitored medical setting. Previous research has shown that a single IV injection of DMT can be given safely, but its effects, which include changes in perception, emotions, and thinking, usually wear off within 15-20 minutes.
To better understand what happens when DMT's effects last longer, researchers have developed a method to give DMT slowly and continuously through an IV, which safely extends its effects for up to an hour or more. In this study, healthy volunteers who have prior experience using DMT will receive low and medium doses of DMT in this extended manner through an IV for 1 hour while undergoing a brain scanning technique known as functional magnetic resonance imaging (fMRI). These scans allow researchers to see changes in brain activity and blood flow in real time.
Participants will complete psychological assessments before and after receiving DMT, and additional brain scans without DMT will be used for comparison. The researchers will also use advanced computer techniques to help identify brain patterns linked to the visual experiences people report during DMT.
Overall, the goal of the study is to better understand how DMT affects the brain during an extended experience and to learn more about the biological processes behind its psychological effects.
Eligibility criteria
Qualifiers
18 to 65 years of age
Able to fluently communicate in English
Agree to sign the consent and HIPAA authorization
Not taking serotonergic antidepressant medication
Disqualifiers
Pregnant or nursing females
Females of childbearing potential who are sexually active but not using birth control
MRI contraindications (e.g., pacemakers, metal implants, spinal cord stimulators)
Current DSM-5 diagnosis of depression or anxiety (or within past 6 months), bipolar disorder, schizophrenia, or other psychotic disorder
Trial design
Treatments tested in this trial
- N,N-Dimethyltryptamine (15 mg)
- N,N-Dimethyltryptamine (17.5 mg)
Treatment groups
Sponsors and collaborators
Jon Dean
Lead sponsor
University of California, San Diego
Sponsor institution